Therapeutic drug monitoring of voriconazole for treatment and prophylaxis of invasive fungal infection in children
Voriconazole therapeutic drug monitoring is not consistently recommended due to its high interpatient and intrapatient variability. Here, we aimed to describe our experience with voriconazole for treatment and prophylaxis of invasive fungal infections in paediatric patients. A fully validated high‐p...
Saved in:
Published in | British journal of clinical pharmacology Vol. 84; no. 1; pp. 197 - 203 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
John Wiley and Sons Inc
01.01.2018
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Voriconazole therapeutic drug monitoring is not consistently recommended due to its high interpatient and intrapatient variability. Here, we aimed to describe our experience with voriconazole for treatment and prophylaxis of invasive fungal infections in paediatric patients. A fully validated high‐performance liquid chromatography–mass spectrometry method was used to quantify voriconazole concentration in plasma, at the end of dosing interval. A high interindividual variability was shown. We enrolled 237 children, 83 receiving intravenous and 154 oral voriconazole. A positive correlation between drug dose and drug plasma exposure was observed. Considering intravenous route, patients with higher serum creatinine had higher voriconazole concentrations; a positive correlation was found among drug exposure and age. Sex significantly influenced drug levels: males had higher median drug concentrations than females (P < 0.001). Close voriconazole pharmacokinetics monitoring should help individualize antifungal therapy for children. |
---|---|
AbstractList | Voriconazole therapeutic drug monitoring is not consistently recommended due to its high interpatient and intrapatient variability. Here, we aimed to describe our experience with voriconazole for treatment and prophylaxis of invasive fungal infections in paediatric patients. A fully validated high‐performance liquid chromatography–mass spectrometry method was used to quantify voriconazole concentration in plasma, at the end of dosing interval. A high interindividual variability was shown. We enrolled 237 children, 83 receiving intravenous and 154 oral voriconazole. A positive correlation between drug dose and drug plasma exposure was observed. Considering intravenous route, patients with higher serum creatinine had higher voriconazole concentrations; a positive correlation was found among drug exposure and age. Sex significantly influenced drug levels: males had higher median drug concentrations than females (
P
< 0.001). Close voriconazole pharmacokinetics monitoring should help individualize antifungal therapy for children. Voriconazole therapeutic drug monitoring is not consistently recommended due to its high interpatient and intrapatient variability. Here, we aimed to describe our experience with voriconazole for treatment and prophylaxis of invasive fungal infections in paediatric patients. A fully validated high-performance liquid chromatography-mass spectrometry method was used to quantify voriconazole concentration in plasma, at the end of dosing interval. A high interindividual variability was shown. We enrolled 237 children, 83 receiving intravenous and 154 oral voriconazole. A positive correlation between drug dose and drug plasma exposure was observed. Considering intravenous route, patients with higher serum creatinine had higher voriconazole concentrations; a positive correlation was found among drug exposure and age. Sex significantly influenced drug levels: males had higher median drug concentrations than females (P < 0.001). Close voriconazole pharmacokinetics monitoring should help individualize antifungal therapy for children.Voriconazole therapeutic drug monitoring is not consistently recommended due to its high interpatient and intrapatient variability. Here, we aimed to describe our experience with voriconazole for treatment and prophylaxis of invasive fungal infections in paediatric patients. A fully validated high-performance liquid chromatography-mass spectrometry method was used to quantify voriconazole concentration in plasma, at the end of dosing interval. A high interindividual variability was shown. We enrolled 237 children, 83 receiving intravenous and 154 oral voriconazole. A positive correlation between drug dose and drug plasma exposure was observed. Considering intravenous route, patients with higher serum creatinine had higher voriconazole concentrations; a positive correlation was found among drug exposure and age. Sex significantly influenced drug levels: males had higher median drug concentrations than females (P < 0.001). Close voriconazole pharmacokinetics monitoring should help individualize antifungal therapy for children. Voriconazole therapeutic drug monitoring is not consistently recommended due to its high interpatient and intrapatient variability. Here, we aimed to describe our experience with voriconazole for treatment and prophylaxis of invasive fungal infections in paediatric patients. A fully validated high‐performance liquid chromatography–mass spectrometry method was used to quantify voriconazole concentration in plasma, at the end of dosing interval. A high interindividual variability was shown. We enrolled 237 children, 83 receiving intravenous and 154 oral voriconazole. A positive correlation between drug dose and drug plasma exposure was observed. Considering intravenous route, patients with higher serum creatinine had higher voriconazole concentrations; a positive correlation was found among drug exposure and age. Sex significantly influenced drug levels: males had higher median drug concentrations than females (P < 0.001). Close voriconazole pharmacokinetics monitoring should help individualize antifungal therapy for children. |
Author | Allegra, Sarah D'Avolio, Antonio Fatiguso, Giovanna Carcieri, Chiara Cusato, Jessica De Francia, Silvia Pirro, Elisa Favata, Fabio De Nicolò, Amedeo Di Perri, Giovanni |
AuthorAffiliation | 2 Department of Biological and Clinical Sciences University of Turin, S. Luigi Gonzaga Hospital Orbassano (TO) Italy 1 Department of Medical Sciences University of Turin – ASL “Città di Torino”, Laboratory of Clinical Pharmacology and Pharmacogenetics, Amedeo di Savoia Hospital Turin Italy |
AuthorAffiliation_xml | – name: 1 Department of Medical Sciences University of Turin – ASL “Città di Torino”, Laboratory of Clinical Pharmacology and Pharmacogenetics, Amedeo di Savoia Hospital Turin Italy – name: 2 Department of Biological and Clinical Sciences University of Turin, S. Luigi Gonzaga Hospital Orbassano (TO) Italy |
Author_xml | – sequence: 1 givenname: Sarah orcidid: 0000-0003-4933-0011 surname: Allegra fullname: Allegra, Sarah email: sarah.allegra@gmail.com organization: University of Turin – ASL “Città di Torino”, Laboratory of Clinical Pharmacology and Pharmacogenetics, Amedeo di Savoia Hospital – sequence: 2 givenname: Giovanna surname: Fatiguso fullname: Fatiguso, Giovanna organization: University of Turin – ASL “Città di Torino”, Laboratory of Clinical Pharmacology and Pharmacogenetics, Amedeo di Savoia Hospital – sequence: 3 givenname: Silvia surname: De Francia fullname: De Francia, Silvia organization: University of Turin, S. Luigi Gonzaga Hospital – sequence: 4 givenname: Fabio surname: Favata fullname: Favata, Fabio organization: University of Turin – ASL “Città di Torino”, Laboratory of Clinical Pharmacology and Pharmacogenetics, Amedeo di Savoia Hospital – sequence: 5 givenname: Elisa surname: Pirro fullname: Pirro, Elisa organization: University of Turin, S. Luigi Gonzaga Hospital – sequence: 6 givenname: Chiara surname: Carcieri fullname: Carcieri, Chiara organization: University of Turin – ASL “Città di Torino”, Laboratory of Clinical Pharmacology and Pharmacogenetics, Amedeo di Savoia Hospital – sequence: 7 givenname: Amedeo surname: De Nicolò fullname: De Nicolò, Amedeo organization: University of Turin – ASL “Città di Torino”, Laboratory of Clinical Pharmacology and Pharmacogenetics, Amedeo di Savoia Hospital – sequence: 8 givenname: Jessica surname: Cusato fullname: Cusato, Jessica organization: University of Turin – ASL “Città di Torino”, Laboratory of Clinical Pharmacology and Pharmacogenetics, Amedeo di Savoia Hospital – sequence: 9 givenname: Giovanni surname: Di Perri fullname: Di Perri, Giovanni organization: University of Turin – ASL “Città di Torino”, Laboratory of Clinical Pharmacology and Pharmacogenetics, Amedeo di Savoia Hospital – sequence: 10 givenname: Antonio orcidid: 0000-0002-1321-4126 surname: D'Avolio fullname: D'Avolio, Antonio organization: University of Turin – ASL “Città di Torino”, Laboratory of Clinical Pharmacology and Pharmacogenetics, Amedeo di Savoia Hospital |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28805964$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kU1v3CAQhlGUqtmkPeQPVBzbgxPGGBtfIjWrfkmRmkNyRhjDLhUGB-xtt7--bHdTtVHKhRnxzPsyM6fo2AevEToHcgH5XHZqvABaEThCC6A1K0oo2TFaEErqgpUMTtBpSt8IAQo1e4lOSs4Ja-tqgeLdWkc56nmyCvdxXuEheDuFaP0KB4M3OVLBy5_BaWxCxFPUchq0n7D0PR5jGNdbJ3_YtKOt38hkN5mc_Uq6nButJht8jrBaW9dH7V-hF0a6pF8f7jN0__HD3fJzcfP105fl-5tCVRygUF0rm9yTrg0waggzPZe8bztp-pYxwzrTQm60lpwR0zRQ0Ya3TUX7kgC0QM_Q1V53nLtB9yr_OUonxmgHGbciSCv-ffF2LVZhI1hDa85oFnh7EIjhYdZpEoNNSjsnvQ5zEtCWvOFlXbGMvvnb64_J46AzcLkHVAwpRW2EspPcjSZbWyeAiN0qRV6l-L3KXPHuScWj6HPsQf27dXr7f1BcL2_3Fb8A5zuv-Q |
CitedBy_id | crossref_primary_10_1002_bmc_5356 crossref_primary_10_1097_MPH_0000000000002898 crossref_primary_10_1002_prm2_12086 crossref_primary_10_1002_prp2_665 crossref_primary_10_1097_FTD_0000000000000952 crossref_primary_10_3897_pharmacia_70_e111511 crossref_primary_10_1002_jcph_2440 crossref_primary_10_1007_s12281_020_00402_6 crossref_primary_10_1080_17512433_2023_2274984 crossref_primary_10_1016_j_microc_2022_107241 crossref_primary_10_1016_j_jpba_2022_114659 crossref_primary_10_1515_chem_2022_0253 crossref_primary_10_3390_pharmaceutics15010266 crossref_primary_10_1002_cpdd_1049 crossref_primary_10_3389_fphar_2021_711187 crossref_primary_10_4155_bio_2023_0020 crossref_primary_10_3390_pharmaceutics13121991 crossref_primary_10_3390_jof4040115 crossref_primary_10_1007_s12281_018_0311_3 crossref_primary_10_1080_1120009X_2024_2376453 crossref_primary_10_1016_j_chroma_2021_462444 crossref_primary_10_3390_antibiotics10121542 crossref_primary_10_1128_AAC_00955_18 crossref_primary_10_1002_jcph_1422 crossref_primary_10_3390_jof8101035 crossref_primary_10_1016_j_ejps_2023_106506 crossref_primary_10_1038_s41598_019_45345_2 crossref_primary_10_1016_j_colsurfb_2018_06_037 crossref_primary_10_1007_s00228_024_03752_z crossref_primary_10_2217_pgs_2022_0159 crossref_primary_10_1097_FTD_0000000000000980 crossref_primary_10_1097_MOP_0000000000000713 crossref_primary_10_1002_cpdd_1218 crossref_primary_10_3389_fphar_2021_755075 crossref_primary_10_1007_s40272_024_00663_5 crossref_primary_10_1080_03602532_2019_1632888 crossref_primary_10_1155_2021_5497427 crossref_primary_10_5863_1551_6776_28_3_247 crossref_primary_10_1186_s13052_024_01684_z crossref_primary_10_3390_jof7060456 crossref_primary_10_3390_molecules27175609 crossref_primary_10_3390_ph14121239 |
Cites_doi | 10.1016/j.ijantimicag.2014.07.013 10.1086/524669 10.1128/AAC.00884-15 10.1093/jac/dku031 10.3324/haematol.2016.152900 10.1164/rccm.2008-740ST 10.1128/AAC.05761-11 10.1038/sj.bmt.1705754 10.1128/AAC.00251-13 10.1097/FTD.0b013e3182241b2b 10.1097/FTD.0b013e31823f3516 10.1128/AAC.00626-12 10.1016/S0149-2918(03)80126-1 10.1128/AAC.01540-12 10.1046/j.1365-2125.2003.01994.x 10.1093/cid/cis437 10.1128/AAC.01807-09 10.1086/648679 10.1002/jps.22109 10.1093/jac/dkt369 10.1007/s10096-008-0543-1 10.1128/AAC.01083-10 10.1093/jac/dks285 10.1016/S1473-3099(15)70006-X 10.1093/cid/cis599 |
ContentType | Journal Article |
Copyright | 2017 The British Pharmacological Society 2017 The British Pharmacological Society. |
Copyright_xml | – notice: 2017 The British Pharmacological Society – notice: 2017 The British Pharmacological Society. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
DOI | 10.1111/bcp.13401 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | CrossRef MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
DocumentTitleAlternate | Voriconazole therapeutic drug monitoring in paediatrics |
EISSN | 1365-2125 |
EndPage | 203 |
ExternalDocumentID | PMC5736853 28805964 10_1111_bcp_13401 BCP13401 |
Genre | shortCommunication Validation Study Journal Article |
GroupedDBID | --- .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1OC 23N 24P 2WC 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5VS 66C 6J9 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABOCM ABPVW ABQWH ABXGK ACAHQ ACCFJ ACCZN ACFBH ACGFO ACGFS ACGOF ACMXC ACPOU ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFPM AFGKR AFPWT AFWVQ AFZJQ AHBTC AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB AOIJS ATUGU AZBYB AZVAB BAFTC BAWUL BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DU5 E3Z EBS EJD EMOBN ESX EX3 F00 F01 F04 F5P FIJ FUBAC G-S G.N GODZA GX1 H.X HF~ HGLYW HYE HZI HZ~ IHE IPNFZ IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LSO LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D Q.N Q11 QB0 R.K ROL RPM RX1 SUPJJ TEORI TR2 UB1 V8K W8V W99 WBKPD WHWMO WIH WIJ WIK WIN WOHZO WOW WQJ WRC WVDHM WXI WXSBR X7M XG1 YFH YOC YUY ZGI ZXP ZZTAW ~IA ~WT AAYXX AEYWJ AGHNM AGYGG CITATION CGR CUY CVF ECM EIF NPM 7X8 AAMMB AEFGJ AGXDD AIDQK AIDYY 5PM |
ID | FETCH-LOGICAL-c4811-cb9a7401e6f153f05fd8a8d9bafd955f5bf912126a850f77143789743d2011913 |
IEDL.DBID | DR2 |
ISSN | 0306-5251 1365-2125 |
IngestDate | Thu Aug 21 14:14:11 EDT 2025 Fri Jul 11 12:38:19 EDT 2025 Thu Apr 03 07:00:17 EDT 2025 Thu Apr 24 22:50:14 EDT 2025 Tue Jul 01 01:59:17 EDT 2025 Wed Jan 22 16:39:54 EST 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | triazoles high-performance liquid chromatography antifungals invasive fungal infections therapeutic drug monitoring |
Language | English |
License | http://onlinelibrary.wiley.com/termsAndConditions#vor 2017 The British Pharmacological Society. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4811-cb9a7401e6f153f05fd8a8d9bafd955f5bf912126a850f77143789743d2011913 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 UNI EN ISO UNI EN ISO 9001:2008 and 13485:2012 (CE‐IVD) Certified Laboratory; Certificate No. IT‐64386. Certification for: “DESIGN, DEVELOPMENT AND APPLICATION OF DETERMINATION METHODS FOR ANTI‐INFECTIVE DRUGS. PHARMACOGENETIC ANALYSES”. |
ORCID | 0000-0002-1321-4126 0000-0003-4933-0011 |
OpenAccessLink | https://bpspubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bcp.13401 |
PMID | 28805964 |
PQID | 1928782645 |
PQPubID | 23479 |
PageCount | 7 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_5736853 proquest_miscellaneous_1928782645 pubmed_primary_28805964 crossref_citationtrail_10_1111_bcp_13401 crossref_primary_10_1111_bcp_13401 wiley_primary_10_1111_bcp_13401_BCP13401 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | January 2018 |
PublicationDateYYYYMMDD | 2018-01-01 |
PublicationDate_xml | – month: 01 year: 2018 text: January 2018 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: Hoboken |
PublicationTitle | British journal of clinical pharmacology |
PublicationTitleAlternate | Br J Clin Pharmacol |
PublicationYear | 2018 |
Publisher | John Wiley and Sons Inc |
Publisher_xml | – name: John Wiley and Sons Inc |
References | 2010; 99 2015; 59 2015; 15 2010; 54 2001 2013; 57 2008; 27 2003; 25 2014; 69 2011; 33 2011; 55 2008; 46 2016 2007; 40 2011; 4 2011; 183 2012; 34 2012; 56 2017; 102 2012; 67 2012; 55 2014; 44 2010; 50 2003; 56 e_1_2_8_28_1 e_1_2_8_29_1 e_1_2_8_24_1 Nomura K (e_1_2_8_3_1) 2008; 27 e_1_2_8_25_1 e_1_2_8_26_1 e_1_2_8_27_1 Lat A (e_1_2_8_31_1) 2011; 4 e_1_2_8_2_1 e_1_2_8_5_1 e_1_2_8_4_1 e_1_2_8_7_1 e_1_2_8_6_1 e_1_2_8_9_1 e_1_2_8_8_1 e_1_2_8_20_1 e_1_2_8_21_1 e_1_2_8_22_1 e_1_2_8_23_1 e_1_2_8_17_1 e_1_2_8_18_1 e_1_2_8_19_1 Shao B (e_1_2_8_30_1) 2016 e_1_2_8_13_1 e_1_2_8_14_1 e_1_2_8_15_1 e_1_2_8_16_1 e_1_2_8_10_1 e_1_2_8_11_1 e_1_2_8_12_1 |
References_xml | – volume: 56 start-page: 3032 year: 2012 end-page: 3042 article-title: Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults publication-title: Antimicrob Agents Chemother – volume: 55 start-page: 1080 year: 2012 end-page: 1087 article-title: The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial publication-title: Clin Infect Dis – volume: 50 start-page: 27 year: 2010 end-page: 36 article-title: Voriconazole pharmacokinetics and pharmacodynamics in children publication-title: Clin Infect Dis – volume: 34 start-page: 77 year: 2012 end-page: 84 article-title: Therapeutic drug monitoring of voriconazole in children publication-title: Ther Drug Monit – volume: 27 start-page: 1141 year: 2008 end-page: 1143 article-title: Pharmacokinetic‐pharmacodynamic analysis of voriconazole in Japanese patients with hematological malignancies publication-title: Eur J Clin Microbiol Infect Dis – volume: 44 start-page: 436 year: 2014 end-page: 442 article-title: Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections publication-title: Int J Antimicrob Agents – volume: 99 start-page: 3291 year: 2010 end-page: 3301 article-title: Review of the basic and clinical pharmacology of sulfobutylether‐beta‐cyclodextrin (SBECD) publication-title: J Pharm Sci – volume: 46 start-page: 201 year: 2008 end-page: 211 article-title: Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes publication-title: Clin Infect Dis – volume: 15 start-page: 461 year: 2015 end-page: 474 article-title: British Society for Medical Mycology best practice recommendations for the diagnosis of serious fungal diseases publication-title: Lancet Infect Dis – volume: 55 start-page: 4782 year: 2011 end-page: 4788 article-title: Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients publication-title: Antimicrob Agents Chemother – volume: 69 start-page: 1633 year: 2014 end-page: 1641 article-title: Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing publication-title: J Antimicrob Chemother – volume: 25 start-page: 1321 year: 2003 end-page: 1381 article-title: Voriconazole publication-title: Clin Ther – volume: 4 start-page: 43 year: 2011 end-page: 53 article-title: Update on the optimal use of voriconazole for invasive fungal infections publication-title: Infect Drug Resist – volume: 69 start-page: 463 year: 2014 end-page: 470 article-title: Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections publication-title: J Antimicrob Chemother – volume: 55 start-page: 381 year: 2012 end-page: 390 article-title: Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics‐based analysis of adult patients with invasive fungal infections publication-title: Clin Infect Dis – start-page: 1 year: 2001 end-page: 56 – volume: 40 start-page: 451 year: 2007 end-page: 456 article-title: Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole publication-title: Bone Marrow Transplant – volume: 59 start-page: 5548 year: 2015 end-page: 5554 article-title: study of the variable effects of proton pump inhibitors on voriconazole publication-title: Antimicrob Agents Chemother – volume: 57 start-page: 3262 year: 2013 end-page: 3267 article-title: Potential factors for inadequate voriconazole plasma concentrations in intensive care unit patients and patients with hematological malignancies publication-title: Antimicrob Agents Chemother – volume: 33 start-page: 464 year: 2011 end-page: 466 article-title: Therapeutic drug monitoring of voriconazole after intravenous administration in infants and children with primary immunodeficiency publication-title: Ther Drug Monit – volume: 67 start-page: 2645 year: 2012 end-page: 2649 article-title: Development and validation of a new method to simultaneously quantify triazoles in plasma spotted on dry sample spot devices and analysed by HPLC‐MS publication-title: J Antimicrob Chemother – volume: 54 start-page: 3408 year: 2010 end-page: 3413 article-title: Development, validation, and routine application of a high‐performance liquid chromatography method coupled with a single mass detector for quantification of itraconazole, voriconazole, and posaconazole in human plasma publication-title: Antimicrob Agents Chemother – volume: 56 start-page: 4793 year: 2012 end-page: 4799 article-title: Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring publication-title: Antimicrob Agents Chemother – volume: 57 start-page: 235 year: 2013 end-page: 240 article-title: Highly variable plasma concentrations of voriconazole in pediatric hematopoietic stem cell transplantation patients publication-title: Antimicrob Agents Chemother – volume: 56 start-page: 17 issue: Suppl 1 year: 2003 end-page: 23 article-title: Effect of food on the pharmacokinetics of multiple‐dose oral voriconazole publication-title: Br J Clin Pharmacol – volume: 183 start-page: 96 year: 2011 end-page: 128 article-title: An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients publication-title: Am J Respir Crit Care Med – start-page: 1 year: 2016 end-page: 9 article-title: Effects of cytochrome P450 3A4 and non‐genetic factors on initial voriconazole serum trough concentrations in hematological patients with different cytochrome P450 2C19 genotypes publication-title: Xenobiotica – volume: 102 start-page: 433 year: 2017 end-page: 444 article-title: ECIL‐6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients publication-title: Haematologica – ident: e_1_2_8_9_1 doi: 10.1016/j.ijantimicag.2014.07.013 – ident: e_1_2_8_16_1 doi: 10.1086/524669 – ident: e_1_2_8_5_1 doi: 10.1128/AAC.00884-15 – ident: e_1_2_8_8_1 doi: 10.1093/jac/dku031 – ident: e_1_2_8_14_1 – ident: e_1_2_8_20_1 doi: 10.3324/haematol.2016.152900 – ident: e_1_2_8_2_1 doi: 10.1164/rccm.2008-740ST – ident: e_1_2_8_25_1 doi: 10.1128/AAC.05761-11 – volume: 4 start-page: 43 year: 2011 ident: e_1_2_8_31_1 article-title: Update on the optimal use of voriconazole for invasive fungal infections publication-title: Infect Drug Resist – ident: e_1_2_8_18_1 doi: 10.1038/sj.bmt.1705754 – ident: e_1_2_8_29_1 doi: 10.1128/AAC.00251-13 – ident: e_1_2_8_12_1 doi: 10.1097/FTD.0b013e3182241b2b – ident: e_1_2_8_6_1 doi: 10.1097/FTD.0b013e31823f3516 – ident: e_1_2_8_19_1 doi: 10.1128/AAC.00626-12 – ident: e_1_2_8_27_1 doi: 10.1016/S0149-2918(03)80126-1 – ident: e_1_2_8_24_1 doi: 10.1128/AAC.01540-12 – ident: e_1_2_8_11_1 doi: 10.1046/j.1365-2125.2003.01994.x – ident: e_1_2_8_15_1 doi: 10.1093/cid/cis437 – ident: e_1_2_8_4_1 – ident: e_1_2_8_13_1 – ident: e_1_2_8_22_1 doi: 10.1128/AAC.01807-09 – ident: e_1_2_8_26_1 doi: 10.1086/648679 – ident: e_1_2_8_28_1 doi: 10.1002/jps.22109 – ident: e_1_2_8_7_1 doi: 10.1093/jac/dkt369 – volume: 27 start-page: 1141 year: 2008 ident: e_1_2_8_3_1 article-title: Pharmacokinetic‐pharmacodynamic analysis of voriconazole in Japanese patients with hematological malignancies publication-title: Eur J Clin Microbiol Infect Dis doi: 10.1007/s10096-008-0543-1 – ident: e_1_2_8_17_1 doi: 10.1128/AAC.01083-10 – start-page: 1 year: 2016 ident: e_1_2_8_30_1 article-title: Effects of cytochrome P450 3A4 and non‐genetic factors on initial voriconazole serum trough concentrations in hematological patients with different cytochrome P450 2C19 genotypes publication-title: Xenobiotica – ident: e_1_2_8_23_1 doi: 10.1093/jac/dks285 – ident: e_1_2_8_21_1 doi: 10.1016/S1473-3099(15)70006-X – ident: e_1_2_8_10_1 doi: 10.1093/cid/cis599 |
SSID | ssj0013165 |
Score | 2.4147277 |
Snippet | Voriconazole therapeutic drug monitoring is not consistently recommended due to its high interpatient and intrapatient variability. Here, we aimed to describe... |
SourceID | pubmedcentral proquest pubmed crossref wiley |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 197 |
SubjectTerms | Administration, Intravenous Administration, Oral Adolescent Age Factors Antifungal Agents - pharmacokinetics Antifungal Agents - therapeutic use antifungals Biological Variation, Population Child Child, Preschool Chromatography, High Pressure Liquid - instrumentation Chromatography, High Pressure Liquid - methods Creatinine - blood Dose-Response Relationship, Drug Drug Monitoring - instrumentation Drug Monitoring - methods Female high‐performance liquid chromatography Humans invasive fungal infections Invasive Fungal Infections - blood Invasive Fungal Infections - therapy Male Mass Spectrometry - instrumentation Mass Spectrometry - methods Sex Factors Short Report therapeutic drug monitoring triazoles Voriconazole - pharmacokinetics Voriconazole - therapeutic use |
Title | Therapeutic drug monitoring of voriconazole for treatment and prophylaxis of invasive fungal infection in children |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fbcp.13401 https://www.ncbi.nlm.nih.gov/pubmed/28805964 https://www.proquest.com/docview/1928782645 https://pubmed.ncbi.nlm.nih.gov/PMC5736853 |
Volume | 84 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3daxQxEB9Kn_qi1s-zWqJI8aF7XG43uwl9qsVSFeWQFvogLPmsh-deuY9i-9d3Jnu7d2cVxLdAZpd8zGR-SSa_AXhTyLznPbeJ8z2TZNKizXGXJ1aK3CDctjKSVX_-kp-cZR_PxfkGHDRvYWp-iPbAjSwjrtdk4NpMV4zc2MsuT7P4dotitQgQfe0vbxB4TCNJkBg3W4IvWIUoiqf9ct0X3QGYd-MkV_FrdEDH9-Fb0_Q67uRHdz4zXXvzG6vjf_btAdxbAFN2WGvSNmz46iHsDWpm6-t9drp8qDXdZ3tssOS8vn4Ek5Vq5ibzC_YzLhZ0asjGgV0RFQmC_pvxyDPEyawNcGe6cgw7hdM90r-GU5IeVleawuoZel30YKyJGKuwxJrn54_h7Pj96dFJskjnkNhMcp5YozTl__N5wGU29ERwUkunjA5OCRGECYqjJ821FL1QUGL2QuJ2J3UEUhRPn8BmNa78M2CFk9aafpb6vsUNsFIiEC-dzJSxRapsB942E1vaBdc5pdwYlc2eB0e4jCPcgdet6GVN8PEnoVeNdpRofnSnois_nk9LBMgSQVaeiQ48rbWl_U0f10ah8qwDxZoetQJE7b1eUw2_R4pvUVBigBT7EdXk7y0r3x0NYuH5v4vuwBaOqKwPkl7A5mwy9y8RWs3MLtrQh0-70ZJuAVXqIyg |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3JbhNBEC2FcIAL-2LWBkHEIWN5lp7pPnCAhMghiyzkSLkN08uAhRlHXgLON_Er_BNVPYttAhKXHLiN1KVRT3VV9aue6lcALxIRd6z1tWdsR3mR0Ohzvok9LXisEG5r4ciqDw7j7lH0_pgfr8GP-i5MyQ_RHLiRZ7h4TQ5OB9JLXq70SdsPMT-oSir37PwbJmyT17vbuLovg2DnXX-r61U9BTwdCd_3tJIZNaGzcY6-nnd4bkQmjFRZbiTnOVe59DGcx5ngnTyh7uCJQMwdGtoppR_iey_BZeogTkz92x-CxT8L3zWuJBCO6R33Kx4jqhtqprq6-52DtOcrM5cRs9vydq7Dz1pZZaXLl_Zsqtr67Dceyf9FmzfgWoW92ZvSWW7Cmi1uwUavJO-eb7L-4i7aZJNtsN6C1nt-G8ZLw8yMZ5_YVxcP6WCUjXJ2SmwrmNecjYaWYSrAmhp-lhWGoRbRoofZ98GEpAfFaUY3BxgCC9ykWV0UV-ATq2_Y34GjC9HHXVgvRoW9DywxQmsVRKENNOb4UvKcqPdEJJVOQqlb8Kq2pFRXdO7UVWSY1mkdrmjqVrQFzxvRk5LD5E9Cz2pzTDHC0G-jrLCj2STFHEAgjowj3oJ7pXk2rwkw_HMZRy1IVgy3ESD28tWRYvDZsZjzhHofhPgdzi7_PrP07VbPPTz4d9GncKXbP9hP93cP9x7CVdSuKM_NHsH6dDyzjxFJTtUT58AMPl60jf8CzgB9TQ |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1LbxMxEB6VIiEuhfJqeBSDoOLQjfblXfvAARqilkIVoVbqbVm_ICJsojwK6V_ir_CjGHsfSShIXHrgtpJHK-94ZvyNd_wNwLOUJb7WgfSU9oUXM4k-F6jEk4wmAuG2ZI6s-v1Rsn8Svz2lp2vwo74LU_JDNAdu1jNcvLYOPlJmycmFHLWDCNODqqLyUM-_Yb42eXnQwcV9HobdN8d7-17VUsCTMQsCTwqe2x50OjHo6sanRrGcKS5yozilhgrDA4zmSc6ob1LbHDxlCLkjZTdKHkT43itwNU58bvtEdD6Ei18WgetbaTE4Znc0qGiMbNlQM9XVze8Cor1YmLkMmN2O170BP2tdlYUuX9qzqWjL899oJP8TZd6EjQp5k1elq2zCmi5uwU6vpO6e75LjxU20yS7ZIb0Fqff8NoyXhokazz6Rry4a2mNRMjTkzHKtYFZzPhxogokAaSr4SV4ogkpEex7k3_sTK90vznJ7b4AgrMAtmtQlcQU-kfp-_R04uRR93IX1YljoLSCpYlKKMI50KDHD55waS7zHYi5kGnHZghe1IWWyInO3PUUGWZ3U4YpmbkVb8LQRHZUMJn8SelJbY4bxxf40ygs9nE0yzAAYosgkpi24V1pn85oQgz_lSdyCdMVuGwHLXb46UvQ_Ow5zmtrOBxF-hzPLv88se73Xcw_3_130MVzrdbrZu4OjwwdwHZXLykOzh7A-Hc_0I4SRU7Ht3JfAx8s28V_Junv8 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Therapeutic+drug+monitoring+of+voriconazole+for+treatment+and+prophylaxis+of+invasive+fungal+infection+in+children&rft.jtitle=British+journal+of+clinical+pharmacology&rft.au=Allegra%2C+Sarah&rft.au=Fatiguso%2C+Giovanna&rft.au=De+Francia%2C+Silvia&rft.au=Favata%2C+Fabio&rft.date=2018-01-01&rft.issn=0306-5251&rft.eissn=1365-2125&rft.volume=84&rft.issue=1&rft.spage=197&rft.epage=203&rft_id=info:doi/10.1111%2Fbcp.13401&rft.externalDBID=n%2Fa&rft.externalDocID=10_1111_bcp_13401 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0306-5251&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0306-5251&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0306-5251&client=summon |